{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:02:23Z","timestamp":1758474143491},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/jcp.0b013e318283925e","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T08:47:44Z","timestamp":1360918064000},"page":"186-192","source":"Crossref","is-referenced-by-count":29,"title":["CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia"],"prefix":"10.1097","volume":"33","author":[{"given":"Weiping","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"De Hert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Moons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan J.","family":"Claes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud","family":"van Winkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210128","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1192\/bjp.171.6.502","article-title":"Excess mortality of schizophrenia. A meta-analysis.","volume":"171","author":"Brown","year":"1997","journal-title":"Br J Psychiatry"},{"key":"R2-7-20210128","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4088\/JCP.08m04718yel","article-title":". Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.","volume":"3","author":"Kelly","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R4-7-20210128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":". Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.","volume":"1","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"R7-7-20210128","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":". Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.","volume":"2","author":"De Hert","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"R8-7-20210128","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":". Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.","volume":"16","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"R9-7-20210128","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients.","volume":"9","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R10-7-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0033291709990407","article-title":". Weight gain in antipsychotic-naive patients: a review and meta-analysis.","volume":"2","author":"Tarricone","year":"2010","journal-title":"Psychol Med"},{"key":"R11-7-20210128","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":". Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice.","volume":"3","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"R14-7-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1463-1326.2009.01038.x","article-title":"Obesity, serious mental illness and antipsychotic drugs.","volume":"7","author":"Holt","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"R15-7-20210128","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/sj.npp.1301051","article-title":"Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents.","volume":"10","author":"Elman","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R16-7-20210128","first-page":"169","article-title":"Metabolic side effects of antipsychotic drug treatmentpharmacological mechanisms.","volume":"1","author":"Reynolds","year":"2009","journal-title":"Pharmacol Ther"},{"key":"R17-7-20210128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity.","volume":"2","author":"Correll","year":"2011","journal-title":"Trends Mol Med"},{"key":"R18-7-20210128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design.","volume":"3","author":"Coccurello","year":"2010","journal-title":"Pharmacol Ther"},{"key":"R19-7-20210128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/clpt.2011.97","article-title":". Mechanisms and genetics of antipsychotic-associated weight gain.","volume":"90","author":"Balt","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R20-7-20210128","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/mp.2011.109","article-title":". Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.","volume":"3","author":"Lett","year":"2012","journal-title":"Mol Psychiatry"},{"key":"R21-7-20210128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/hup.1122","article-title":". Genetic association between TNF-alpha -308 GA polymorphism and longitudinal weight change during clozapine treatment.","volume":"4","author":"Wang","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"R22-7-20210128","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.v69n0909","article-title":". Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.","volume":"9","author":"Ujike","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R23-7-20210128","first-page":"15","article-title":". Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia.","volume":"1","author":"Jassim","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R24-7-20210128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/JCP.0b013e3181934462","article-title":". HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.","volume":"1","author":"Mulder","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R25-7-20210128","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0140-6736(02)08913-4","article-title":"Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism.","volume":"9323","author":"Reynolds","year":"2002","journal-title":"Lancet"},{"key":"R26-7-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-011-2211-x","article-title":". Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication.","volume":"2","author":"Vehof","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R27-7-20210128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/JCP.0b013e3181fbfac4","article-title":". Association between the 1291-CG polymorphism in the adrenergic alpha-2a receptor and the metabolic syndrome.","volume":"6","author":"Risselada","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R28-7-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2741\/3675","article-title":". Lipogenic effects of psychotropic drugs: focus on the SREBP system.","volume":"16","author":"Ferno","year":"2011","journal-title":"Front Biosci"},{"key":"R29-7-20210128","first-page":"396","article-title":". Antipsychotic drugs up-regulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol.","volume":"5","author":"Kristiana","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"R30-7-20210128","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.pnpbp.2008.08.014","article-title":". Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis.","volume":"8","author":"Souza","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R31-7-20210128","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/JCP.0b013e3181fae248","article-title":". Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment.","volume":"6","author":"Perez-Iglesias","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R34-7-20210128","first-page":"9","article-title":". The implication of CNR1 genes polymorphisms in the modulation of endocannabinoid system effects.","volume":"1","author":"Dinu","year":"2009","journal-title":"Rom J Intern Med"},{"key":"R35-7-20210128","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.mp.4001029","article-title":". CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia.","volume":"5","author":"Ujike","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R36-7-20210128","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ajmg.b.30592","article-title":". Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia.","volume":"3","author":"Chavarria-Siles","year":"2008","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R37-7-20210128","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/hmg\/ddn089","article-title":". Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations.","volume":"13","author":"Benzinou","year":"2008","journal-title":"Hum Mol Genet"},{"key":"R39-7-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1155\/2008\/841490","article-title":". Cannabinoid type-1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population.","volume":"1","author":"Jaeger","year":"2008","journal-title":"Dis Markers"},{"key":"R40-7-20210128","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00406-009-0024-2","article-title":"Cannabis and psychosisschizophrenia: human studies.","volume":"7","author":"DSouza","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R41-7-20210128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00213-009-1612-6","article-title":". Role of cannabis and endocannabinoids in the genesis of schizophrenia.","volume":"4","author":"Fernandez-Espejo","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"R42-7-20210128","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1196\/annals.1367.024","article-title":"The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.","volume":"1083","author":"Kyrou","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"R43-7-20210128","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/sj.npp.1301375","article-title":". Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids.","volume":"11","author":"Carriba","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R44-7-20210128","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.neuroimage.2010.04.034","article-title":". Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand 11COMAR.","volume":"4","author":"Wong","year":"2010","journal-title":"Neuroimage"},{"key":"R45-7-20210128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2146\/060258","article-title":"Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.","volume":"5","author":"Patel","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"R46-7-20210128","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/oby.2011.250","article-title":". The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabants antiobesity effects in mice.","volume":"10","author":"Pang","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"R47-7-20210128","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ymgme.2008.07.008","article-title":". Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes.","volume":"3","author":"Aberle","year":"2008","journal-title":"Mol Genet Metab"},{"key":"R48-7-20210128","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2217\/14622416.9.11.1647","article-title":". Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index.","volume":"11","author":"Baye","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R49-7-20210128","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1210\/jc.2006-2523","article-title":". Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men.","volume":"6","author":"Russo","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R50-7-20210128","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.metabol.2010.01.028","article-title":". Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity.","volume":"2","author":"de Luis","year":"2011","journal-title":"Metabolism"},{"key":"R51-7-20210128","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/dmrr.1200","article-title":". Relation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification.","volume":"5","author":"de Luis","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"R52-7-20210128","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00439-010-0878-4","article-title":". A large-scale candidate gene association study of age at menarche and age at natural menopause.","volume":"5","author":"He","year":"2010","journal-title":"Hum Genet"},{"key":"R53-7-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ymgme.2007.01.002","article-title":". No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents.","volume":"4","author":"Muller","year":"2007","journal-title":"Mol Genet Metab"},{"key":"R54-7-20210128","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/npp.2009.235","article-title":". A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia.","volume":"6","author":"Tiwari","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R55-7-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e3181e742c5","article-title":". Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359GA CNR1 polymorphism is associated with antipsychotic-induced weight gain.","volume":"4","author":"Monteleone","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R58-7-20210128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.schres.2005.12.855","article-title":". Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.","volume":"1","author":"De Hert","year":"2006","journal-title":"Schizophr Res"},{"key":"R59-7-20210128","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4088\/JCP.v69n0817","article-title":". Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program.","volume":"8","author":"van Winkel","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R61-7-20210128","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":". Diagnosis and management of the metabolic syndrome: an American Heart AssociationNational Heart, Lung, and Blood Institute Scientific Statement.","volume":"17","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"R62-7-20210128","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2337\/dc08-S055","article-title":"Diagnosis and classification of diabetes mellitus.","volume":"31","year":"2008","journal-title":"Diabetes Care"},{"key":"R63-7-20210128","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/archgenpsychiatry.2010.152","article-title":"Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up.","volume":"68","author":"van Winkel","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"R64-7-20210128","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/ejhg.2009.85","article-title":". Recovering unused information in genome-wide association studies: the benefit of analyzing SNPs out of Hardy-Weinberg equilibrium.","volume":"12","author":"Fardo","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"R65-7-20210128","first-page":"34","article-title":"Hardy-Weinberg equilibrium tests and allele frequency estimation.","volume":"8","author":"Cleves","year":"1999","journal-title":"STATA Technical Bulletin"},{"key":"R66-7-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajmg.b.31174","article-title":". Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction.","volume":"3","author":"Decoster","year":"2011","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R67-7-20210128","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(05)67424-7","article-title":"Genetic association studies.","volume":"9491","author":"Cordell","year":"2005","journal-title":"Lancet"},{"key":"R68-7-20210128","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1530\/EJE-10-0192","article-title":". Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution.","volume":"3","author":"Frost","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"R69-7-20210128","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3109\/09513590.2011.569796","article-title":". Endocannabinoid type 1 receptor gene (CNR1) polymorphisms (rs806381, rs10485170, rs6454674, rs2023239) and cardiovascular risk factors in postmenopausal women.","volume":"12","author":"Laczmanski","year":"2011","journal-title":"Gynecol Endocrinol"},{"key":"R71-7-20210128","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.arcmed.2010.07.010","article-title":"G1359A polymorphism in the cannabinoid receptor-1 gene is associated with metabolic syndrome in the Chinese Han population.","volume":"5","author":"Hu","year":"2010","journal-title":"Arch Med Res"},{"key":"R72-7-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0269881111408458","article-title":"The role of the endocannabinoid system in the neuroendocrine regulation of energy balance.","volume":"26","author":"Bermudez-Silva","year":"2012","journal-title":"J Psychopharmacol"},{"key":"R73-7-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-642-17214-4_4","article-title":"Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.","volume":"203","author":"Di Marzo","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"R74-7-20210128","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1172\/JCI34827","article-title":". Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.","volume":"9","author":"Osei-Hyiaman","year":"2008","journal-title":"J Clin Invest"},{"key":"R75-7-20210128","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/ijo.2011.55","article-title":". Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.","volume":"12","author":"Bell-Anderson","year":"2011","journal-title":"Int J Obes (Lond)"},{"key":"R76-7-20210128","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s00125-008-1048-2","article-title":"The endocannabinoid system in obesity and type 2 diabetes.","volume":"8","author":"Di Marzo","year":"2008","journal-title":"Diabetologia"},{"key":"R77-7-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.metabol.2008.10.009","article-title":". Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients.","volume":"3","author":"Sarzani","year":"2009","journal-title":"Metabolism"},{"key":"R78-7-20210128","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":". Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.","volume":"5","author":"Osei-Hyiaman","year":"2005","journal-title":"J Clin Invest"},{"key":"R79-7-20210128","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","article-title":". The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.","volume":"3","author":"Cota","year":"2003","journal-title":"J Clin Invest"},{"key":"R80-7-20210128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1152\/ajpgi.00059.2010","article-title":". Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype.","volume":"1","author":"Burdyga","year":"2010","journal-title":"Am J PhysiolGastrointest Liver Physiol"},{"key":"R81-7-20210128","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1210\/en.2005-1649","article-title":". Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function.","volume":"4","author":"Cota","year":"2007","journal-title":"Endocrinology"},{"key":"R82-7-20210128","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1152\/ajpgi.00543.2005","article-title":". Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance.","volume":"6","author":"Burdyga","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e318283925e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:00:59Z","timestamp":1620957659000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201304000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318283925e","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}